申联生物 (688098.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.6x

Market Cap

CNY 3.29B

MomentumView details →

1D Return

−3.03%

YTD Return

—

RSI (14)

49.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.6x

Market Cap

CNY 3.29B

RSI (14)

49.4

MomentumView details →

1D Return

−3.03%

YTD Return

—

ProfitabilityView details →

Gross Margin

57.71%

Net Margin

−7.06%

EBITDA Margin

17.33%

ROE (TTM)

−1.38%

ROA (TTM)

−1.26%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

−7.47%

EPS YoY

+57.21%

FCF YoY

—

Revenue CAGR 3Y

−4.27%

EPS CAGR 3Y

+54.55%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.00x

Quick Ratio

3.11x

Div Yield

—

Div Rate

—

Div Growth 1Y

−56.25%

Financials snapshotView financials →

Revenue (TTM)

272.12M

Net Income (TTM)

−19.21M

Op. CF (TTM)

21.56M

Latest newsMore news →

Shenlian Biotech appointed Gao Xu as deputy general manager, effective from the board meeting date until the end of the fourth board term.6d ago

Shenlian Biologic reported its first-half 2026 results: revenue of 112 million yuan, down 8.05% year-on-year; net loss attributable to shareholders of 19.1464 million yuan, compared with a net loss of 12.8697 million yuan in the same period last year; non-recurring net loss of 19.1558 million yuan; R&D investment accounted for 19.91% of revenue, down 2.41 percentage points year-on-year.6d ago

Similar companies

之江生物688317.SH HJ Science Co., Ltd.06132.HK Laekna, Inc.02105.HK Structure Therapeutics Inc.GPCR Veracyte, Inc.VCYT 硕世生物688399.SH Find similar companies →

Latest newsMore news →

Shenlian Biotech appointed Gao Xu as deputy general manager, effective from the board meeting date until the end of the fourth board term.6d ago Shenlian Biologic reported its first-half 2026 results: revenue of 112 million yuan, down 8.05% year-on-year; net loss attributable to shareholders of 19.1464 million yuan, compared with a net loss of 12.8697 million yuan in the same period last year; non-recurring net loss of 19.1558 million yuan; R&D investment accounted for 19.91% of revenue, down 2.41 percentage points year-on-year.6d ago